Form 4: ADMA Biologics Director Boosts Stake with Equity Grants

ADMA Biologics Director Young Kwon acquired 10,690 restricted stock units and 17,730 stock options, increasing beneficial ownership.

Summary

• Director Young Kwon of ADMA Biologics acquired 10,690 Restricted Stock Units (RSUs) and 17,730 stock options on February 9, 2026.
• The RSUs will vest in two equal installments on the sixand twelve-month anniversaries of the grant date, becoming fully vested on February 9, 2027, contingent on continued service.
• The stock options, with an exercise price of $16.37, will vest in twelve equal monthly installments, becoming fully vested on February 9, 2027, and have an expiration date of February 9, 2036.
• Following these transactions, Young Kwon beneficially owns a total of 263,020 shares of common stock and 17,730 stock options.
• The total beneficial ownership of common stock includes the 10,690 newly granted RSUs, 5,445 previously granted RSUs (from February 19, 2025, vesting fully on February 19, 2026), and 246,885 directly owned common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an insider increasing their stake, even through grants, suggests continued commitment and alignment with shareholder interests, though it's not an open market purchase.

Positives

• A director increasing their stake in the company through RSU and option grants can signal confidence in the company's future performance.
• The equity grants align the director's long-term interests with shareholder value through vesting schedules tied to continued service.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon the reporting person's continued service to the company.
• The value realized from the stock options is dependent on the future market price of ADMA common stock exceeding the exercise price of $16.37.

Future Outlook

The grants of restricted stock units and stock options with multi-year vesting schedules indicate an expectation of continued service from Director Young Kwon and a long-term focus on aligning management incentives with future company performance.

Industry Context

StockSavvy.ai notes that equity grants to directors and executives are a standard practice in the biotechnology and pharmaceutical industries, serving to attract and retain talent while aligning their interests with long-term shareholder value. These grants often include vesting schedules to incentivize sustained performance and commitment, a common feature seen across companies like Regeneron Pharmaceuticals and Amgen.

Comparison to Industry Standards

• The use of RSUs and stock options as part of director compensation is a standard practice in the U.S. public market, comparable to compensation structures at companies such as Gilead Sciences and Biogen, which also utilize performance-based equity awards.
• The vesting schedule of one year for full vesting of RSUs and options is within typical industry ranges, though some companies might use longer periods (e.g., 3-4 years) for executive performance shares, reflecting a balance between retention and immediate incentive.
• The exercise price of $16.37 for the stock options is set at the market price on the grant date, which is standard for non-qualified stock options, ensuring that the options only gain value if the stock price appreciates from that point.

Stakeholder Impact

• Shareholders: Potential positive signal of director confidence; aligns director's long-term interests with shareholder value.

Next Steps

• Continued service by Young Kwon to ensure the vesting of RSUs and stock options.
• Future Form 4 filings will report any subsequent changes in beneficial ownership by Young Kwon.

Key Dates

Recommendation

While the Form 4 indicates a director's increased stake through equity grants, signaling confidence and aligning interests, it does not provide sufficient fundamental or operational data to warrant a 'buy' or 'sell' recommendation. The grants are part of compensation, not an open market purchase, suggesting a 'hold' as a neutral stance pending further financial disclosures.

Keywords

ADMA Biologics, ADMA, Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSUs, Director Compensation, Beneficial Ownership, Young Kwon